Finding an Effective Dose of GM1 to Reduce or Prevent Neuropathy (Numbness or Weakness) Due to Treatment With Paclitaxel (Phase II)

Recruiting

Phase 2

Finding an Effective Dose of GM1 to Reduce or Prevent Neuropathy (Numbness or Weakness) Due to Treatment With Paclitaxel (Phase II)

Sponsor:

Alliance for Clinical Trials in Oncology

Code:

NCT05751668

Conditions

Anatomic Stage IV Breast Cancer AJCC v8

Chemotherapy-Induced Peripheral Neuropathy

Metastatic Breast Carcinoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Paclitaxel

Monosialotetrahexosylganglioside

Questionnaire Administration

Quality-of-life assessment

Placebo Administration

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-06-16. This information was provided to ClinicalTrials.gov by Alliance for Clinical Trials in Oncology on 2025-04-02.